Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months

Park, So Yun; Kim, Sung Hoon; Chae, Hee Dong; Kim, Chung-Hoon; Kang, Byung Moon

추천

검색

자료유형: 학술저널

저자정보: Park, So Yun (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) Kim, Sung Hoon (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) Chae, Hee Dong (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) Kim, Chung-Hoon (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) Kang, Byung Moon (Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine)

저널정보: 대한생식의학회 Clinical and experimental reproductive medicine : CERM Clinical and experimental reproductive medicine : CERM 제43권 제4호

발행연도: 2016.1

수록면: 215 - 220 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: To evaluate the efficacy and safety of dienogest treatment in patients who had received dienogest for 12 months or more to treat endometriosis. Methods: We analyzed the clinical data of 188 women with endometriosis who had been treated with 2 mg of dienogest once a day for 12 months or more at a single institute. We evaluated changes in endometriosis-associated pain and endometrioma size, recurrence rate, and adverse events following dienogest administration. Bone mineral density (BMD) was measured in patients who were prescribed dienogest for more than 18 months. Results: Pain was significantly reduced at 12 months after dienogest medication. In those treated with dienogest due to recurrent endometrioma, the size of the endometrioma was significantly decreased at the 12-month and 18-month follow-ups. We found only one case of sonographic recurrence during dienogest administration among those who were treated postoperatively to prevent recurrence (1 of 114, 0.9%). The most common adverse drug reaction was uterine bleeding (3.2%), and other adverse events were generally tolerable and associated with low discontinuation rates (5.2%). Among the 50 patients in whom BMD was measured, 10 patients (20%) had a Z-score below the expected range for age. Conclusion: The administration of dienogest for a year or more seems to be highly effective in preventing recurrence after surgery, reducing endometriosis-associated pain, and decreasing the size of recurrent endometrioma, with a favorable safety and tolerability profile. However, BMD should be checked in patients on long-term medication due to possible bone loss in some women.

#Bone density #Dienogest #Endometriosis #Long-term care #Recurrence

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!